The bill amends sections 3902.50 and 3902.70 of the Revised Code and enacts a new section 3902.72, which establishes regulations regarding the actions of drug manufacturers in relation to 340B covered entities. Specifically, it prohibits manufacturers, repackagers, and third-party logistics providers from denying or limiting the acquisition and delivery of 340B drugs to grantees, as well as from requiring claims or utilization data as a condition for such transactions. The bill also defines key terms related to the 340B drug pricing program and outlines penalties for violations, including civil penalties and potential referral to the state board of pharmacy.

Additionally, the bill updates the numbering of certain sections and repeals existing sections 3902.50, 3902.70, and 3902.72. It introduces new definitions and clarifies the responsibilities of health plan issuers and pharmacy benefit managers in providing data related to drug coverage and cost-sharing. The provisions are set to take effect on January 1, 2022, ensuring that the new regulations align with federal laws and regulations.

Statutes affected:
As Introduced: 3902.50, 3902.70, 3902.72, 3902.75